PolyPid Regains European Rights to D-PLEX100 From ADVANZ PHARMA
PolyPid has regained exclusive European commercialization rights for its D-PLEX100 drug by terminating its 2022 agreement with ADVANZ PHARMA. This strategic shift follows recent Phase 3 success and submissions for regulatory approval in Europe and the US, prompting PolyPid to seek new partnerships.